Eight therapies have outgrown the IPM growth
The Indian Pharma Market (IPM) clocked Rs 8601 crores in October 2015. It has grown at 21.8 per cent in the same month. Amongst the top 10, Pfizer grew by 25.4 per cent followed by GSK at 23.9 per cent and Abbott at 23.6 per cent. 22 corporates have crossed the growth of IPM for October 2015 amongst top 50.
Amongst the top 50 corporates, Bharat Serums has the highest growth of 62.7 per cent followed by AstraZeneca at 57 per cent and Wockhardt at 50.4 per cent. 45 corporates have shown growths of more than 10 per cent amongst the top 50.
Amongst the 11-20 ranked corporates, Glenmark has the highest growth of 43.6 per cent followed by Micro at 33.6 per cent and Alembic at 31.4 per cent. Amongst the 21-30 ranked corporates, Wockhardt has the highest growth at 50.4 per cent followed by MSD at 40.1 per cent and Unichem at 26.6 per cent. Amongst the 31-40 ranked corporates, Bharat Serums was at 62.7 per cent, AstraZeneca has the highest growth at 57 per cent and JBCPL at 43.7 per cent. Amongst the 41-50 ranked corporates, Troikaa has the highest growth at 37 per cent followed by Hetero at 30.6 per cent and Win-Medicare at 18.9 per cent. Amongst the 51-60 ranked corporates, Boehringer Ingelheim grew at 69.6 per cent followed by Centaur at 37.2 per cent and Corona at 33.4 per cent. Amongst the 61-70 ranked corporates, Fresenius Kabi grew at 66.8 per cent followed by RPG by 37.9 per cent followed by Geno at 23.6 per cent.
MSD has entered the Rs 1,000-crore club, Bharat Serums entered the Rs 500 crore club, Hegde & Hegde in Rs 300-crore club, Geno Pharma in Rs 200-crore club, Veritaz in Rs 100-crore club on MAT basis.
Ind-Swift and Shreya who had declined for years are staging a strong revival on growth as well as six months trends look positive. 100-plus ranked companies like Alarsin and Vanguard are showing a strong positive upswing on monthly basis.
For the month of October 2015, amongst the top 10, Abbott HC grew by 27.6 per cent followed by Pfizer at 25.4 per cent and GSK at 23.9 per cent. 23 companies have crossed the growth of IPM for the month of October 2015 amongst top 50.
Zuventus grows by 27.4 per cent, Novo by 22.8 per cent, Alkem by 20.6 per cent and MSD by 53 per cent. Indian companies have grown at 21.4 per cent versus 23.5 per cent for MNCs in October 2015. Amongst the top 50 in MNCs, AstraZeneca grew at 57 per cent, MSD grew by 40.1 per cent followed by and Pfizer at 25.4 per cent. Under the Non-NLEM category Indian companies grew at 22.6 per cent whereas MNCs grew at 24.1 per cent.
The DPCO containing molecules market grew at 15.4 per cent whereas the non-DPCO market grew by 22.9 per cent and Non -Sch Para 19 Market at 20.9 per cent resulting in an overall growth of 21.8 per cent.
NLEM and Non – NLEM category showed unit growth at 13.4 per cent and 11.7 per cent respectively. The Non-Sch Para 19 market grew at 16 per cent from units perspective.
From therapy perspective, eight therapies have outgrown the IPM growth. The respiratory market grew at 21.8 per cent, the gastrointestinal market grew at 22.4 per cent, pain and analgesics market grew at 21.1 per cent whereas anti-infectives grew at 22.1 per cent. The anti-diabetic market grew at 29.8 per cent and cardiac at 21.1 per cent in chronic business. The derma market grew by 23.2 per cent and urology market at 19.5 per cent.
From regional perspective, 14 regions have outgrown the IPM growth. Haryana market grew the highest at 34.9 per cent followed by South AP market at 33 per cent and North AP market at 32.3 per cent. No regions had negative growth in October 2015.
Amoxycillin + Clavulanic acid market grew at 17.8 per cent whereas Glimepiride + Metformin grows at 20.9 per cent at number two. The markets of paracetamol grew at 46.2 per cent, atorvastatin 15.5 per cent, probiotic microbes at 27.6 per cent, cefixime 22.3 per cent, pantoprazole 20.6 per cent, montelukast + levocetrizine at 23.7 per cent, glimepiride + metformin + pioglitazone at 24.3 per cent,Vvitamin-D at 29.5 per cent, hydroquinone + mometasone + tretinoin at -4.4 per cent, voglibose + metformin + glimepiride at 51.8 per cent, rosuvastatin at 28.1 per cent, protein supplements at 17.7 per cent, Azithromycin at 18.4 per cent, calcium carbonate + Vit D3 market at 28.2 per cent.
Mixtard leads the pack with Rs 35 crores followed Monocef at Rs 33 crores, Corex at Rs 32 crores for October 2015. Few brands who have gained ranks include meronem (+167), rotarix (+95), trajenta (+46), betnovate c (+45), cardace (+41), betnesol (+40), betnovate n (+38), rantac (+36), mucaine (+32), panderm plus rhoclone (+29), omez (+28), spasmoproxyvon plus, ascoril plus(+23), deriphyllin (+22), januvia, mifegest kit (+20), istamet (+18), calpol (+17), magnex (+15), jalra , dolo, vertin(+14), pantop (+13), telma (+12), janumet, shelcal (+11), sinarest (+4), amongst top 100 brands over october 2014. Few brands that have moved up ranks fastest into top 300 brands for the month of october 2015 are brilinta, lonopin, dexona, mero, meronem, glizid M, bevon amongst others. 300th biggest brand is Bifilac from Tablets India.
A total of 223 brands and 421 SKUs were launched in October 2015. Top new brands for October 2015 were Zitamet Plus, Ixarola, Jardiance. Biggest new launch by an MNC were Jardiance, Dulcosoft, Optive Fusion.
About PharmaTrac
PharmaTrac is the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocdawacs.com/
Comments are closed.